Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT-709478 in Photosensitive Epilepsy (Phase 2a PD/PK Study)
2017-000494-36Phase 2Completed
- Sponsor
- Idorsia
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-blind, single-arm trial of NBI-827104 in photosensitive epilepsy (PSE), sponsored by Idorsia. Primary endpoint: Individual evaluation of the response to intermittent photic stimulation. Started Jun 2017; status: completed.
02
Drugs
NBI-827104
03
Conditions
photosensitive epilepsy (PSE)
Beyond the preview
Go deeper on 2017-000494-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000494-36.